I disagree with you completely. I am here for the entire fruit basket Lympro, MSPrecise, Nuropro, Phenogard, Eltoprazine, ESS, MANF RP as well as other indications. You are essentially saying all of it is of not much value. If you are here because you think MANF is potentially the greatest therapeutic molecule ever, that's great. But to suggest investors should not be concerned about the day to day share price and how our newly launched diagnostic impacts is ignorant IMO. I am here 1. because I believe MANF has great potential 2. believe Eltoprazine shows promise with a large market 3. I believe ALZ is going to explode and snowball continuously as a main focus priority of BP, small pharm, government, sports science etc. Thus our suite of diagnostics for ALZ can grow to enormous value. 4. Now bc I believe MS precise has promise with a potential large market.....To suggest we should all look at everything outside of MANF as a meal ticket and checking account for MANF progression solely is absurd IMO. Lastly, every investor has the right and should care about the PPS before a split occurs if needed at all again im not going to explain how this is better for shareholders and the strength and outlook of the company! A company with a PPS @.65 with 800 million shares is obviously stronger than where we are at now!
I disagree with you completely. I am here for the entire
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Nvidia's Stock Surge: The Hidden Strategy Behind Growth
Nvidia's stock surged in 2023 like a rocket ship headed to the moon, making traders sit up and take notice. With its reputation firmly planted in tech innovation, it managed to pull off a jaw-dropping comeback after a sell-off earlier in the year. Resilience Amidst Market Whirlwind This wasn't just any bounce-back; we’re talking about a solid 13% uptick in weeks when...
Continue Reading
Yoshiharu Global Co. Implements 4-for-1 Stock Split Strategy
Yoshiharu Global Co. Announces a Significant Stock Split Yoshiharu Global Co. (NASDAQ: YOSH), an innovative restaurant operator specializing in authentic Japanese ramen and rolls, has made an important announcement regarding its stock. The company’s Board of Directors has authorized a 4-for-1 forward stock split to enhance shareholder engagement and market activity....
Continue Reading
Viatris Unveils Tender Offer Pricing for Senior Notes
Viatris Sets Pricing for Senior Notes Tender Offers Viatris Inc. (NASDAQ: VTRS) is moving ahead with cash tender offers for certain senior notes and has announced the pricing terms. The effort is part of a broader plan to streamline outstanding debt and sharpen the company’s financial profile. In practical terms, Viatris is offering to buy back targeted notes for cash...
Continue Reading
AB Akola Group Aims for Growth in Feed Production Capacity
AB Akola Group's Ambitious Expansion Plans AB Akola Group, one of the prominent agricultural and food production organizations in the Baltic region, is gearing up for an exciting chapter of growth and innovation. With ownership of the well-known company Kauno Gr?dai, the group is focusing on enhancing its production capabilities to remain competitive in the market. A...
Continue Reading
Global Paraxylene Demand to Surge by 2034, Insights Revealed
A Surge in Paraxylene Demand Ahead The global market for paraxylene, a crucial compound in the production of polyester fibers and PET resin, is witnessing significant growth. Market analysts predict that the volume could reach a staggering 96.40 million tons by 2034, marking a steady growth rate of 4.59% annually from the year 2025 onwards. The driving forces behind this...
Continue Reading